

# Drug-Resistant Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DC32638C090EEN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: DC32638C090EEN

## Abstracts

The 7 major drug-resistant epilepsy markets reached a value of US\$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 6.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034.

The drug-resistant epilepsy market has been comprehensively analyzed in IMARC's new report titled "Drug-Resistant Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Drug-resistant epilepsy, also known as refractory epilepsy, refers to a form of neurological disorder in which seizures are not adequately controlled or eliminated by anti-seizure medications. The disease is characterized by recurrent seizures, that are caused by abnormal electrical activity in the brain. This condition can have a significant impact on the patient's quality of life, affecting their physical and mental well-being, ability to work or drive, and overall daily functioning. The most common indications associated with the illness include visual disturbance, unusual taste, muscle weakness, difficulty speaking, numbness, tingling, sensory or motor impairment, memory problems, mood swings, irritability, depression, low blood sugar, fainting, etc. The diagnosis of drug-resistant epilepsy is mainly based on a combination of clinical feature evaluation, medical history assessment, physical examination, and neuropsychological tests. An electroencephalogram is also used, which helps in detecting abnormal brain wave patterns and identifying the location and type of seizures. The healthcare provider may further perform several diagnostic studies, such as single-photon emission computed tomography and magnetic resonance imaging, to visualize metabolic activities in the brain.

The rising cases of brain structural abnormalities, like tumors and vascular

malformations, resulting from previous brain injuries or surgeries, which can alter the electrical network and interfere with the effectiveness of anti-seizure medications, are primarily driving the drug-resistant epilepsy market. In addition to this, the increasing incidences of inherited defects, that cause genetic variations in drug-metabolizing enzymes, drug transporters, or target receptors are also propelling the market growth. Moreover, the escalating application of effective therapeutic agents, including cannabidiol, felbamate, vigabatrin, etc., to manage the symptoms of drug-resistant epilepsy is creating a positive outlook for the market. Additionally, the inflating demand for neurofeedback therapy, a non-invasive technique to potentially encourage self-regulation and increase independence in daily activities of patients, is acting as another significant growth-inducing factor. Furthermore, the widespread adoption of neuromodulation devices, such as vagus nerve stimulation, responsive neurostimulation, deep brain stimulation, etc., since they continuously monitor brain activity and deliver electrical stimulation to the affected regions in order to disrupt the abnormal brain patterns and reduce seizures, is expected to drive the drug-resistant epilepsy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the drug-resistant epilepsy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for drug-resistant epilepsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the drug-resistant epilepsy market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the drug-resistant epilepsy market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the drug-resistant epilepsy market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current drug-resistant epilepsy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance  
Key Questions Answered in this Report:  
Market Insights

How has the drug-resistant epilepsy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the drug-resistant epilepsy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the drug-resistant epilepsy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of drug-resistant epilepsy across the seven major markets?

What is the number of prevalent cases (2018-2034) of drug-resistant epilepsy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of drug-resistant epilepsy by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with drug-resistant epilepsy across the seven major markets?

What is the size of the drug-resistant epilepsy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of drug-resistant epilepsy?

What will be the growth rate of patients across the seven major markets?

### Drug-Resistant Epilepsy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for drug-resistant epilepsy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the drug-resistant epilepsy market?

What are the key regulatory events related to the drug-resistant epilepsy market?

What is the structure of clinical trial landscape by status related to the drug-resistant epilepsy market?

What is the structure of clinical trial landscape by phase related to the drug-resistant epilepsy market?

What is the structure of clinical trial landscape by route of administration related to the drug-resistant epilepsy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 DRUG-RESISTANT EPILEPSY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 DRUG-RESISTANT EPILEPSY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 DRUG-RESISTANT EPILEPSY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 DRUG-RESISTANT EPILEPSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 DRUG-RESISTANT EPILEPSY - UNMET NEEDS**

## **10 DRUG-RESISTANT EPILEPSY - KEY ENDPOINTS OF TREATMENT**

## **11 DRUG-RESISTANT EPILEPSY - MARKETED PRODUCTS**

- 11.1 List of Drug-Resistant Epilepsy Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 DRUG-RESISTANT EPILEPSY - PIPELINE DRUGS**

### 12.1 List of Drug-Resistant Epilepsy Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. DRUG-RESISTANT EPILEPSY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. DRUG-RESISTANT EPILEPSY – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 DRUG-RESISTANT EPILEPSY - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Drug-Resistant Epilepsy - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Drug-Resistant Epilepsy - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Drug-Resistant Epilepsy - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Drug-Resistant Epilepsy - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 Drug-Resistant Epilepsy - Market Size

#### 15.4.1.1 Market Size (2018-2023)

#### 15.4.1.2 Market Forecast (2024-2034)

### 15.4.2 Drug-Resistant Epilepsy - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (2018-2023)

#### 15.4.2.2 Market Forecast by Therapies (2024-2034)

### 15.4.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 Drug-Resistant Epilepsy - Market Size

#### 15.5.1.1 Market Size (2018-2023)

#### 15.5.1.2 Market Forecast (2024-2034)

### 15.5.2 Drug-Resistant Epilepsy - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (2018-2023)

#### 15.5.2.2 Market Forecast by Therapies (2024-2034)

### 15.5.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 Drug-Resistant Epilepsy - Market Size

#### 15.6.1.1 Market Size (2018-2023)

#### 15.6.1.2 Market Forecast (2024-2034)

### 15.6.2 Drug-Resistant Epilepsy - Market Size by Therapies

#### 15.6.2.1 Market Size by Therapies (2018-2023)

#### 15.6.2.2 Market Forecast by Therapies (2024-2034)

### 15.6.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## 15.7 Market Scenario - Italy

### 15.7.1 Drug-Resistant Epilepsy - Market Size

#### 15.7.1.1 Market Size (2018-2023)

#### 15.7.1.2 Market Forecast (2024-2034)

### 15.7.2 Drug-Resistant Epilepsy - Market Size by Therapies

#### 15.7.2.1 Market Size by Therapies (2018-2023)

#### 15.7.2.2 Market Forecast by Therapies (2024-2034)

### 15.7.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Drug-Resistant Epilepsy - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Drug-Resistant Epilepsy - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Drug-Resistant Epilepsy - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Drug-Resistant Epilepsy - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Drug-Resistant Epilepsy - Access and Reimbursement Overview

## **16 DRUG-RESISTANT EPILEPSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 DRUG-RESISTANT EPILEPSY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 DRUG-RESISTANT EPILEPSY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Drug-Resistant Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DC32638C090EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC32638C090EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

